Page 5 - Nasdaq Imrx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer Preclinical data package now includes animal studies...

Immuneering Co. (NASDAQ:IMRX – Get Rating) Director Laurie Keating bought 7,000 shares of Immuneering stock in a transaction on Monday, May 16th. The stock was acquired at an average price of $5.00 per share, for a total transaction of $35,000.00. Following the transaction, the director now directly owns 14,000 shares of the company’s stock, valued […]

Wall Street brokerages expect that Immuneering Co. (NASDAQ:IMRX – Get Rating) will post sales of $220,000.00 for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Immuneering’s earnings, with estimates ranging from $190,000.00 to $300,000.00. The company is expected to announce its next earnings results on Monday, January 1st. […]

Equities analysts expect that Immuneering Co. (NASDAQ:IMRX – Get Rating) will announce earnings per share (EPS) of ($0.44) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Immuneering’s earnings, with estimates ranging from ($0.46) to ($0.40). The firm is expected to report its next earnings report on Monday, January 1st. […]

Immuneering Co. (NASDAQ:IMRX – Get Rating) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 1,930,000 shares, a growth of 43.0% from the March 15th total of 1,350,000 shares. Approximately 10.1% of the company’s stock are short sold. Based on an average trading […]